2023
Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive association
2014
Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers
Xu F, Zhang H, Su Y, Kong J, Yu H, Qian B. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clinical And Translational Oncology 2014, 16: 980-985. PMID: 24805982, DOI: 10.1007/s12094-014-1183-9.Peer-Reviewed Original ResearchConceptsFemale lung adenocarcinomaLung adenocarcinomaLung tissueTianjin Medical University Cancer HospitalCorresponding normal lung tissuesCox proportional hazards modelMiR-183-3pProgression-free survivalLymph node metastasisLog-rank testNoncancerous lung tissuesPoor overall survivalLung cancer pathogenesisNormal lung tissuesLung cancer tissuesAdjacent noncancerous tissuesPotent prognostic markerPotential prognostic biomarkerProportional hazards modelT-testStudent's t-testBackgroundLung cancerOverall survivalNode metastasisClinicopathological characteristics
2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
2008
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 2008, 101: 48-60. PMID: 19116382, PMCID: PMC2639294, DOI: 10.1093/jnci/djn415.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBiomarkers, TumorBlood GlucoseBody Mass IndexBreast NeoplasmsCase-Control StudiesEstradiolEstrogen Replacement TherapyFemaleHumansHyperinsulinismInsulinInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMiddle AgedMultivariate AnalysisObesityOdds RatioPostmenopauseProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsStatistics, NonparametricConceptsInsulin-like growth factorLevels of insulinBreast cancerInsulin levelsRisk factorsPostmenopausal womenGrowth factorMultiple breast cancer risk factorsMultivariable Cox proportional hazards modelsWomen's Health Initiative Observational StudyBreast cancer case subjectsBreast cancer risk factorsCox proportional hazards modelHormone therapy useIncident breast cancerIndependent risk factorPostmenopausal breast cancerCancer risk factorsCase-cohort studyProportional hazards modelTotal IGFNondiabetic womenBaseline characteristicsFree IGFProspective cohortHigh miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2005
A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer
McClusky D, Chu Q, Yu H, DeBenedetti A, Johnson L, Meschonat C, Turnage R, McDonald J, Abreo F, Li B. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer. Annals Of Surgery 2005, 123: 278-286. PMID: 16192819, PMCID: PMC1402342, DOI: 10.1097/01.sla.0000184224.55949.90.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBlotting, WesternBreast NeoplasmsElectrophoresis, Polyacrylamide GelEukaryotic Initiation Factor-4EFemaleFollow-Up StudiesHumansIncidenceLymph NodesLymphatic MetastasisMastectomy, Extended RadicalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesRisk FactorsSurvival RateConceptsNode-positive breast cancerBreast cancerCancer recurrenceHighest tertileEIF4E overexpressionProspective trialNodal statusHigher cancer recurrence rateCancer-related death rateCox proportional hazards modelNode-positive diseaseKaplan-Meier methodCancer recurrence rateLog-rank testCancer-related deathProportional hazards modelRelative risk increaseHigh eIF4E overexpressionRelative risk calculationsMedian followDisease recurrenceIndependent predictorsIntermediate tertileNoncancer patientsProspective study
2004
IGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomenGenetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z, Cai Q, Shu X, Cai H, Li C, Yu H, Gao Y, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 1290-5. PMID: 15298948, DOI: 10.1158/1055-9965.1290.13.8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionBase SequenceBiomarkers, TumorBreast NeoplasmsCase-Control StudiesChinaConfidence IntervalsFemaleGenetic Predisposition to DiseaseHumansIncidenceInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsMiddle AgedMolecular Sequence DataOdds RatioPolymerase Chain ReactionPolymorphism, GeneticPopulation SurveillanceReference ValuesRisk AssessmentConceptsInsulin-like growth factorIGFBP-3 protein levelsBreast cancer riskBreast cancerVariant allelesIGFBP3 polymorphismsIGFBP-3IGFBP3 geneCancer riskElevated riskRisk genotypesActions of IGFsIncident breast cancer patientsChinese womenIGFBP-3 levelsIGF binding proteinBreast cancer patientsGenetic polymorphismsIGFBP-3 proteinProtein levelsCase-control studyDose-response mannerCancer patientsOdds ratioPolymorphism A
2003
Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics.
Dai Q, Franke A, Yu H, Shu X, Jin F, Hebert J, Custer L, Gao Y, Zheng W. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiology Biomarkers & Prevention 2003, 12: 497-502. PMID: 12814993.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnthropometryBiomarkers, TumorBody Mass IndexBody WeightBreast NeoplasmsCase-Control StudiesChinaDehydroepiandrosterone SulfateEatingEstrogensFemaleFibroadenomaHumansIsoflavonesMenopauseMiddle AgedPhytoestrogensPlant PreparationsRisk FactorsSex Hormone-Binding GlobulinStatistics as TopicTestosteroneWomen's HealthConceptsBody mass indexBreast cancer riskUrinary phytoestrogen excretionSteroid sex hormonesSex hormonesCancer riskSteroid hormonesUrinary isoflavonoidsBlood levelsInverse associationBreast cancerExcretion rateEndogenous steroid sex hormonesHigher body mass indexMammalian lignansConditional logistic regression modelsPotential confounding factorsHigh blood concentrationsCase-control pairsPotential protective associationLogistic regression modelsPostmenopausal womenMorning bloodMass indexHip ratio
2002
Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome
Li B, Gruner J, Abreo F, Johnson L, Yu H, Nawas S, McDonald J, DeBenedetti A. Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome. Annals Of Surgery 2002, 235: 732-739. PMID: 11981220, PMCID: PMC1422500, DOI: 10.1097/00000658-200205000-00016.Peer-Reviewed Original ResearchConceptsCancer-related deathCancer recurrenceRelative riskBreast cancerIndependent predictorsReceptor statusProtein elevationHigh eIF4EMenopausal statusTumor sizeTumor gradeHigher cancer recurrence rateImportant independent prognostic markerKaplan-Meier survival curvesCox proportional hazards modelStage 1Progesterone receptor statusBreast cancer outcomesSmall retrospective studiesStage of diseaseEstrogen receptor statusCancer recurrence rateIndependent prognostic markerLog-rank testBreast cancer recurrence
2001
Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collectionIGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage age
1999
Re: Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells
Yu H. Re: Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells. Journal Of The National Cancer Institute 1999, 91: 1685-1685. PMID: 10511597, DOI: 10.1093/jnci/91.19.1685.Peer-Reviewed Original ResearchEnhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
Yu H, Spitz M, Mistry J, Gu J, Hong W, Wu X. Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis. Journal Of The National Cancer Institute 1999, 91: 151-156. PMID: 9923856, DOI: 10.1093/jnci/91.2.151.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorLung cancer riskHigher plasma levelsPlasma levelsIGFBP-3Lung cancerControl subjectsIGF-IICancer riskOdds ratioLevels of IGFIGFBP-3 plasma levelsGrowth factorIGFBP-3 levelsPlasma IGFBP-3Primary lung cancerIGF-binding proteinsCase-control studyLung cancer developmentCase-control analysisEnzyme-linked immunosorbentPossible causal roleIGF variablesCase patientsConsecutive patients
1998
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBreast NeoplasmsCohort StudiesCytosolFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPloidiesPrognosisProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneS PhaseSurvival AnalysisTime FactorsUnited StatesConceptsProstate-specific antigenPrimary breast cancerBreast cancerCohort studyPrognostic valueRelative riskBreast tumorsSteroid hormone receptor levelsLow S-phase fractionMeasurement of PSAPSA-negative patientsPSA-positive patientsPrognosis of patientsYounger patient ageHormone receptor levelsLarge cohort studyUnited States cohort studyValuable tumor markerS-phase fractionUnited States patientsBreast tumor extractsMedian followPSA presenceNodal statusPatient age
1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptorsCreatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.Peer-Reviewed Original ResearchConceptsCK-BB levelsCK-BBTumor cytosolsEstrogen receptor-negative cancersEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancer patientsRisk of deathReceptor-negative cancersRisk of relapseBreast tumor cytosolsHistological typeClinicopathological variablesPatient survivalPrognostic indicatorTumor stageAggressive tumorsCancer patientsProgesterone receptorUnivariate analysisHigh riskBB groupIsoenzyme levelsPatientsBreast tumors
1995
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage